Effectiveness of Leuprolide acetate therapy every three months in central precocious puberty;Efectividad de la terapia con leuprolide acetato de depósito cada tres meses en pubertad precoz central

Revista Medica de Chile

Volumn 134, Issue 7, 2006, Pages 821-826

  Mericq G, M Verónica ^a   Youlton R, Ronald ^a   Willshaw Z, M Eugenia ^b  

^a CLÍNICA LAS CONDES   (Chile)

^b HOSPITAL MILITAR DE SANTIAGO   (Chile)

Author keywords

Gonadotropins; Leuprolide; Puberty, precocious

Indexed keywords

FERTILITY PROMOTING AGENT; GONADORELIN; LEUPRORELIN; LUTEINIZING HORMONE; TESTOSTERONE;

AGE DETERMINATION; ARTICLE; BLOOD; BODY HEIGHT; BONE DENSITY; BONE DEVELOPMENT; BREAST; CHILD; CLINICAL TRIAL; DRUG EFFECT; DRUG POTENTIATION; FEMALE; GROWTH, DEVELOPMENT AND AGING; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; METABOLISM; MULTICENTER STUDY; OVARY; PHYSIOLOGY; PRECOCIOUS PUBERTY; TESTIS;

AGE DETERMINATION BY SKELETON; BODY HEIGHT; BONE DENSITY; BONE DEVELOPMENT; BREAST; CHILD; FEMALE; FERTILITY AGENTS; GONADOTROPIN-RELEASING HORMONE; HUMANS; INJECTIONS, INTRAMUSCULAR; LEUPROLIDE; LUTEINIZING HORMONE; MALE; OVARY; PUBERTY, PRECOCIOUS; TESTIS; TESTOSTERONE;

EID: 33748496045     PISSN: 00349887     EISSN: 07176163     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. CODNER E, UNANUE N, GAETE X, BARRERA A, MOOKKANAMORI D, BAZÁES R ET AL. [Age of pubertal events in Chilean school age girls and its relationship with socioeconomic status and body mass index]. Rev Méd Chil 2004; 132: 801-8.
2. KAPLOWITZ PB, OBERFIELD SE. Reexamination of the age limit for defining when puberty is precocious in girls in the United States: implications for evaluation and treatment. Drug and Therapeutics and Executive Committees of the Lawson Wilkins Pediatric Endocrine Society. Pediatrics 1999; 104: 936-41.
3. GARCÍA H, YOULTON R, BURROWS R, CATANI A. [Consensus on the diagnosis and treatment of central early puberty]. Rev Méd Chile 2003; 131: 95-110.
4. WILDT L, MARSHALL G, KNOBIL E. Experimental induction of puberty in the infantile female rhesus monkey. Science 1980; 207: 1373-5.
5. OKADA H. One- and three-month release injectable microspheres of the LH-RH superagonist leuprorelin acetate. Adv Drug Deliv Rev 1997; 28: 43-70.
6. CROWLEY WF JR, COMITE F, VALE W, RIVIER J, LORIAUX DL, CUTLER GB JR. Therapeutic use of pituitary desensitization with a long-acting LHRH agonist: a potential new treatment for idiopathic precocious puberty. J Clin Endocrinol Metab 1981; 52: 370-2.
7. KLEIN KO, BARNES KM, JONES JM, FEUILLAN PP, CUTLER GB JR. Increased final height in precocious puberty after long-term treatment with LHRH agonists: the National Institutes of Health experience. J Clin Endocrinol Metab 2001; 86: 4711-6.
8. CAREL JC, LAHLOU N, JARAMILLO O, MONTAUBAN V, TEINTURIER C, COLLE ET AL. Treatment of central precocious puberty by subcutaneous injections of leuprorelin 3-month depot (11.25 mg). J Clin Endocrinol Metab 2002; 87: 4111-6.
9. NEELY EK, HINTZ RL, WILSON DM, LEE PA, GAUTIER T, ARGENTE J ET AL. Normal ranges for immunochemiluminometric gonadotropin assays. J Pediatr 1995; 127: 40-6.
10. MARSHALL WA, TANNER JM. Variations in pattern of pubertal changes in girls. Arch Dis Child 1969; 44: 291-303.
11. KHAN MS, O'BRIEN A. An evaluation of pharmacokinetics and pharmacodynamics of leuprorelin acetate 3M-depot in patients with advanced and metastatic carcinoma of the prostate. Urol Int 1998; 60: 33-40.
12. WECHSEL HW, ZERBIB M, PAGANO F, COPTCOAT MJ. Randomized open labelled comparative study of the efficacy, safety and tolerability of leuprorelin acetate 1M and 3M depot in patients with advanced prostatic cancer. Eur Urol 1996; 30 Suppl 1: 7-14; discussion 19-21.
13. NEELY EK, BACHRACH LK, HINTZ RL, HABIBY RL, SLEMENDA CW, FEEZLE L ET AL. Bone mineral density during treatment of central precocious puberty. J Pediatr 1995; 127: 819-22.
14. ANTONIAZZI F, ZAMBONI G, BERTOLDO F, LAURIOLA S, MENGARDA F, PIETROBELLI A ET AL. Bone mass at final height in precocious puberty after gonadotropin-releasing hormone agonist with and without calcium supplementation. J Clin Endocrinol Metab 2003; 88: 1096-101.
15. CLEMONS RD, KAPPY MS, STUART TE, PERELMAN AH, HOEKSTRA FT. Long-term effectiveness of depot gonadotropin-releasing hormone analogue in the treatment of children with central precocious puberty. Am J Dis Child 1993; 147: 653-7.
16. KAPLAN SL, GRUMBACH MM. Clinical review 14: Pathophysiology and treatment of sexual precocity. J Clin Endocrinol Metab 1990; 71: 785-9.
17. PARKER KL, BAENS-BAILON RG, LEE PA. Depot leuprolide acetate dosage for sexual precocity. J Clin Endocrinol Metab 1991; 73: 50-2.
18. TANAKA T, HIBI I, KATO K, SAITO S, SHIMIZU N, SUWA S ET AL. A dose finding study of a super long-acting luteinizing hormone-releasing hormone analog (leuprolide acetate depot, TAP-144-SR) in the treatment of central precocious puberty. The TAP-144-SR CPP Study Group. Endocrinol Jpn 1991; 38: 369-76.